Insider Buying: Tivic Health Systems (NASDAQ:TIVC) Director Acquires $10,400.00 in Stock

Tivic Health Systems, Inc. (NASDAQ:TIVC) Director Sheryle Bolton acquired 10,000 shares of the stock in a transaction that occurred on Wednesday, April 15th. The stock was purchased at an average price of $1.04 per share, for a total transaction of $10,400.00. Following the completion of the transaction, the director owned 10,000 shares in the company, valued at $10,400. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link.

Tivic Health Systems Price Performance

Shares of NASDAQ TIVC opened at $1.14 on Thursday. The firm has a market capitalization of $3.28 million, a P/E ratio of -0.17 and a beta of 1.84. Tivic Health Systems, Inc. has a one year low of $0.72 and a one year high of $7.74. The company’s fifty day moving average is $0.93 and its two-hundred day moving average is $1.56. The company has a debt-to-equity ratio of 0.38, a quick ratio of 20.13 and a current ratio of 20.13.

Tivic Health Systems (NASDAQ:TIVC) last issued its earnings results on Monday, March 30th. The company reported ($1.03) EPS for the quarter, topping the consensus estimate of ($408.00) by $406.97.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Tivic Health Systems in a research report on Monday. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, Tivic Health Systems has an average rating of “Sell”.

Tivic Health Systems Company Profile

Tivic Health Systems is a commercial-stage medical technology company that develops and markets non-drug, neuromodulation-based therapies for nasal and sinus health. The company’s solutions are designed to alleviate sinus pain, pressure and congestion through gentle microcurrent and vibration stimulation. By targeting the underlying nerve pathways in the nasal passages, Tivic Health aims to provide an alternative to over-the-counter and prescription medications without introducing systemic side effects.

The flagship product, ClearUP™ Sinus Pain Relief, is an FDA-cleared, hand-held device intended for home use.